Press Kit

The figure above (on page 1) shows how Rametrix™ works and what information is returned to caregivers. A patient (with unknown CKD status and stage) submits a urine specimen, which is then scanned using a Raman spectrometer. The resulting spectrum is combined with hundreds of spectra from the Rametrix TM Database, which are from patients with known CKD status and stage. Multivariate statistics are applied using the Rametrix TM Computational Pipeline to process the Raman spectral data and produce “s entinel cluste rs” of Raman spectra. These “sentinel clusters” are generated based on hundreds of different molecules in the specimen that differ significantly between healthy individuals and patients with different stages of CKD. Further action by the Rametrix™ Computational Pipeline reduces the “sentinel clusters” into easily-read and understood numerical values , termed a “KRam Score” (on a scale of 0-100 Rams, a proprietary unit of measure). The KRam Score corresponds with CKD status and stage. In the figure above (on page 1), the yellow circle represents the spectrum from the patient with unknown CKD status and stage. Physicians and healthcare providers do not need to learn to read cluster plots to utilize Rametrix™ . Individual patient data is reduced to a single, meaningful KRam Score. In the example above (on page 1), the nephrologist would receive a KRam Score of 21.5 Rams (out of 100) as the result of the Rametrix TM screen for the patient with unknown CKD status and stage. This corresponds to CKD Stage 1. In addition, nephrologists have the option of screening patients repeatedly over time or with medical intervention to determine if and at what rate the Rametrix TM screen result changes. Being fast and inexpensive, Rametrix TM offers nephrologists a new tool to collect abundant data on their patients and track CKD progression more efficiently. Status of Intellectual Property and IP Protection Strategy An initial patent application for Rametrix™ technolo gy was filed in 2014. Additional patent filings for specific applications (applications such as CKD and bladder cancer screening) have also been submitted. The technology has been exclusively licensed to the technology’s inventors. We believe there are no competing technologies that are as rapid, economical, and logistically sensible, and that have the capability for mass annual screening of millions of people at risk for developing CKD. About DialySensors, Inc. DialySensors, Inc. is a healthcare technology company based in Blacksburg, VA. It was co- founded by Drs. John Robertson and Ryan Senger, the inventors of the Rametrix™ technology. Dr. Robertson (CEO) brings 40 years of experience in nephrology, pathology, oncology research, and medical device development. Dr. Senger (CTO) has 20 years of experience in chemical/biological engineering, Raman spectroscopy, and systems biology. Dr. Dick Daugherty recently joined the company as COO; he has over 30 years of experience in leading new technology-based businesses and corporate ventures. The company collaborates with dozens of nephrologists, urologists, surgeons, oncologists, and other healthcare professionals on numerous ongoing proof-of-concept and validation studies in academic, corporate and government settings. The shared goal of the DialySensors team and their collaborators is to use Rametrix™ technology to improve patient care and quality of life – while reducing healthcare costs.

© 2018, DialySensors, Inc.

Page 2 of 2